Cargando…
MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
BACKGROUND: Chronic visual loss is a disabling feature in patients with multiple sclerosis (MS). It was recently shown that MD1003 (high-dose pharmaceutical-grade biotin or hdPB) may improve disability in patients with progressive MS. OBJECTIVE: The aim of this study was to evaluate whether MD1003 i...
Autores principales: | Tourbah, Ayman, Gout, Olivier, Vighetto, Alain, Deburghgraeve, Véronique, Pelletier, Jean, Papeix, Caroline, Lebrun-Frenay, Christine, Labauge, Pierre, Brassat, David, Toosy, Ahmed, Laplaud, David-Axel, Outteryck, Olivier, Moreau, Thibault, Debouverie, Marc, Clavelou, Pierre, Heinzlef, Olivier, De Sèze, Jérôme, Defer, Gilles, Sedel, Frédéric, Arndt, Carl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061426/ https://www.ncbi.nlm.nih.gov/pubmed/29808469 http://dx.doi.org/10.1007/s40263-018-0528-2 |
Ejemplares similares
-
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
por: Tourbah, Ayman, et al.
Publicado: (2016) -
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
por: Barbin, Laetitia, et al.
Publicado: (2016) -
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021) -
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019) -
Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study
por: Wilson, Sarah, et al.
Publicado: (2022)